BioCentury
ARTICLE | Clinical News

Atacand candesartan cilexetil: Phase III data

September 29, 2008 7:00 AM UTC

In the 4-year, double-blind, international Phase III DIRECT-Prevent 1 trial in 1,421 Type 1 diabetics without retinopathy, Atacand narrowly missed the primary endpoint of significantly lowering the in...